Ertapenem+Meropenem Including Double Carbapenem Therapy (EMDCT) Versus Ceftazidime-Avibactam Therapy In The Therapy Of Carbapenem-Resistant Klebsiella Pneumoniae Infections (CRKPI): A Retrospective Matched Cohort Study
BACKGROUND-AIM: In this retrospective matched cohort study, we aimed to compare the clinical outcomes of EMDCT including therapy receiving cases with ceftazidime/avibactam (CAZAVI) receiving CRKPI cases. MATERIALS/METHODS: This study was performed at a 1800+ bedded tertiary-care educational universi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716524001851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846106952322514944 |
|---|---|
| author | Merve Mert Vahabi Deniz Dağ Şevket Yeniyol Gamze Şanlıdağ Deniz Akyol Seichan Ketentzi Dilşah Başkol Buse Kenanoğlu Nazlıhan Yalçın Şükrü Dirik Arda Kaya Uğur Önal Hüseyin Aytaç Erdem Hüsnü Pullukçu Meltem Taşbakan Tansu Yamazhan Bilgin Arda Sercan Ulusoy Oğuz Reşat Sipahi |
| author_facet | Merve Mert Vahabi Deniz Dağ Şevket Yeniyol Gamze Şanlıdağ Deniz Akyol Seichan Ketentzi Dilşah Başkol Buse Kenanoğlu Nazlıhan Yalçın Şükrü Dirik Arda Kaya Uğur Önal Hüseyin Aytaç Erdem Hüsnü Pullukçu Meltem Taşbakan Tansu Yamazhan Bilgin Arda Sercan Ulusoy Oğuz Reşat Sipahi |
| author_sort | Merve Mert Vahabi |
| collection | DOAJ |
| description | BACKGROUND-AIM: In this retrospective matched cohort study, we aimed to compare the clinical outcomes of EMDCT including therapy receiving cases with ceftazidime/avibactam (CAZAVI) receiving CRKPI cases. MATERIALS/METHODS: This study was performed at a 1800+ bedded tertiary-care educational university hospital. Adult (>18 years old) patients with culture proven CRKPI (bacteremia, pneumonia, urinary tract infections (UTI), intraabdominal infections (IAI)) treated with EMDCT or CAZAVI including regimens between August 2016 and October 2023 were included in the study. Matching was performed as one CAZAVI matched to minimum 1 or 2 EMDCT when n is possible according to the sample infecting strain was yielded (bacteremia vs. bacteremia etc.) Blood cultures were performed on Bact-Alert (Bio Merioux, France). Antimicrobial susceptibility tests were performed via VITEK 2 system (bioMérieux). Resistance to carbapenems was tested by E-test (bioMérieux). The results were interpreted according to the EUCAST criteria. RESULTS: A total of 69 patients(25 female, aged 63,14±13,74), 42 cases in EMDCT group and 27 cases in cef-avi group diagnosed with CRKPN bacteremia (18 cases), pneumonia (24 cases), UTI(18 cases), IAI (9 cases) were included in the study. Age, gender, duration of therapy, all cause day 30 mortality in the overall cohort, bacteremia, UTI, pneumonia subgroups, end of treatment clinical and microbiological response, relapse and reinfection in one mont post-treatment follow up rates did not differ significantly between two cohorts (Table-1). CONCLUSIONS: Although the number of cases is relatively low and non-randomized, CAZAVI and EMDCT containing therapy resulted in quiet similar outcome in our matched cohort study. |
| format | Article |
| id | doaj-art-c5be8e88199a4bf089685a7feecc83dc |
| institution | Kabale University |
| issn | 2213-7165 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Global Antimicrobial Resistance |
| spelling | doaj-art-c5be8e88199a4bf089685a7feecc83dc2024-12-27T04:08:13ZengElsevierJournal of Global Antimicrobial Resistance2213-71652024-12-01393Ertapenem+Meropenem Including Double Carbapenem Therapy (EMDCT) Versus Ceftazidime-Avibactam Therapy In The Therapy Of Carbapenem-Resistant Klebsiella Pneumoniae Infections (CRKPI): A Retrospective Matched Cohort StudyMerve Mert Vahabi0Deniz Dağ1Şevket Yeniyol2Gamze Şanlıdağ3Deniz Akyol4Seichan Ketentzi5Dilşah Başkol6Buse Kenanoğlu7Nazlıhan Yalçın8Şükrü Dirik9Arda Kaya10Uğur Önal11Hüseyin Aytaç Erdem12Hüsnü Pullukçu13Meltem Taşbakan14Tansu Yamazhan15Bilgin Arda16Sercan Ulusoy17Oğuz Reşat Sipahi18Ege University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeKanuni Sultan Süleyman Research and Training Hospital, İstanbul TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeUludağ University, Faculty of Medicine Infectious Diseases and Clinical Microbiology, Bursa, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeEge University Faculty of Medicine Infectious Diseases and Clinical Microbiology, İzmir, TürkiyeBACKGROUND-AIM: In this retrospective matched cohort study, we aimed to compare the clinical outcomes of EMDCT including therapy receiving cases with ceftazidime/avibactam (CAZAVI) receiving CRKPI cases. MATERIALS/METHODS: This study was performed at a 1800+ bedded tertiary-care educational university hospital. Adult (>18 years old) patients with culture proven CRKPI (bacteremia, pneumonia, urinary tract infections (UTI), intraabdominal infections (IAI)) treated with EMDCT or CAZAVI including regimens between August 2016 and October 2023 were included in the study. Matching was performed as one CAZAVI matched to minimum 1 or 2 EMDCT when n is possible according to the sample infecting strain was yielded (bacteremia vs. bacteremia etc.) Blood cultures were performed on Bact-Alert (Bio Merioux, France). Antimicrobial susceptibility tests were performed via VITEK 2 system (bioMérieux). Resistance to carbapenems was tested by E-test (bioMérieux). The results were interpreted according to the EUCAST criteria. RESULTS: A total of 69 patients(25 female, aged 63,14±13,74), 42 cases in EMDCT group and 27 cases in cef-avi group diagnosed with CRKPN bacteremia (18 cases), pneumonia (24 cases), UTI(18 cases), IAI (9 cases) were included in the study. Age, gender, duration of therapy, all cause day 30 mortality in the overall cohort, bacteremia, UTI, pneumonia subgroups, end of treatment clinical and microbiological response, relapse and reinfection in one mont post-treatment follow up rates did not differ significantly between two cohorts (Table-1). CONCLUSIONS: Although the number of cases is relatively low and non-randomized, CAZAVI and EMDCT containing therapy resulted in quiet similar outcome in our matched cohort study.http://www.sciencedirect.com/science/article/pii/S2213716524001851multidrug resistancecarbapenem resistancecarbapenems |
| spellingShingle | Merve Mert Vahabi Deniz Dağ Şevket Yeniyol Gamze Şanlıdağ Deniz Akyol Seichan Ketentzi Dilşah Başkol Buse Kenanoğlu Nazlıhan Yalçın Şükrü Dirik Arda Kaya Uğur Önal Hüseyin Aytaç Erdem Hüsnü Pullukçu Meltem Taşbakan Tansu Yamazhan Bilgin Arda Sercan Ulusoy Oğuz Reşat Sipahi Ertapenem+Meropenem Including Double Carbapenem Therapy (EMDCT) Versus Ceftazidime-Avibactam Therapy In The Therapy Of Carbapenem-Resistant Klebsiella Pneumoniae Infections (CRKPI): A Retrospective Matched Cohort Study Journal of Global Antimicrobial Resistance multidrug resistance carbapenem resistance carbapenems |
| title | Ertapenem+Meropenem Including Double Carbapenem Therapy (EMDCT) Versus Ceftazidime-Avibactam Therapy In The Therapy Of Carbapenem-Resistant Klebsiella Pneumoniae Infections (CRKPI): A Retrospective Matched Cohort Study |
| title_full | Ertapenem+Meropenem Including Double Carbapenem Therapy (EMDCT) Versus Ceftazidime-Avibactam Therapy In The Therapy Of Carbapenem-Resistant Klebsiella Pneumoniae Infections (CRKPI): A Retrospective Matched Cohort Study |
| title_fullStr | Ertapenem+Meropenem Including Double Carbapenem Therapy (EMDCT) Versus Ceftazidime-Avibactam Therapy In The Therapy Of Carbapenem-Resistant Klebsiella Pneumoniae Infections (CRKPI): A Retrospective Matched Cohort Study |
| title_full_unstemmed | Ertapenem+Meropenem Including Double Carbapenem Therapy (EMDCT) Versus Ceftazidime-Avibactam Therapy In The Therapy Of Carbapenem-Resistant Klebsiella Pneumoniae Infections (CRKPI): A Retrospective Matched Cohort Study |
| title_short | Ertapenem+Meropenem Including Double Carbapenem Therapy (EMDCT) Versus Ceftazidime-Avibactam Therapy In The Therapy Of Carbapenem-Resistant Klebsiella Pneumoniae Infections (CRKPI): A Retrospective Matched Cohort Study |
| title_sort | ertapenem meropenem including double carbapenem therapy emdct versus ceftazidime avibactam therapy in the therapy of carbapenem resistant klebsiella pneumoniae infections crkpi a retrospective matched cohort study |
| topic | multidrug resistance carbapenem resistance carbapenems |
| url | http://www.sciencedirect.com/science/article/pii/S2213716524001851 |
| work_keys_str_mv | AT mervemertvahabi ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT denizdag ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT sevketyeniyol ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT gamzesanlıdag ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT denizakyol ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT seichanketentzi ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT dilsahbaskol ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT busekenanoglu ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT nazlıhanyalcın ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT sukrudirik ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT ardakaya ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT uguronal ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT huseyinaytacerdem ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT husnupullukcu ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT meltemtasbakan ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT tansuyamazhan ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT bilginarda ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT sercanulusoy ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy AT oguzresatsipahi ertapenemmeropenemincludingdoublecarbapenemtherapyemdctversusceftazidimeavibactamtherapyinthetherapyofcarbapenemresistantklebsiellapneumoniaeinfectionscrkpiaretrospectivematchedcohortstudy |